[1] Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies[J]. Circulation, 1996, 93(5):841-842. [2] Corrado D, Basso C, Nava A, et al. Arrhythmogenic right ventricular cardiomyopathy:current diagnostic and management strategies[J]. Cardiol Rev, 2001, 9(5):259-265. [3] Azaouagh A, Churzidse S, Konorza T,et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy:a review and update[J]. Clin Res Cardiol, 2011, 100(5):383-394. [4] Lodder EM, Rizzo S. Mouse models in arrhythmogenic right ventricular cardiomyopathy[J]. Front Physiol, 2012, 3:221. [5] Lombardi R, da Graca Cabreira-Hansen M, Bell A,et al. Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy[J]. Circ Res, 2011, 109(12):1342-1353. [6] Takahashi K,Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors[J]. Cell, 2007, 131(5):861-872. [7] Yang C, Al-Aama J, Stojkovic M,et al. Concise review:cardiac disease modeling using induced pluripotent stem cells[J]. Stem Cells, 2015, 33(9):2643-2651. [8] Jiang Y, Habibollah S, Tilgner K,et al. An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional differences in HLHS-derived cardiac myocytes[J]. Stem Cells Transl Med, 2014, 3(4):416-423. [9] Nelson TJ, Martinez-Fernandez A, Terzic A. Induced pluripotent stem cells:developmental biology to regenerative medicine[J]. Nat Rev Cardiol, 2010, 7(12):700-710. [10] Rajamohan D, Matsa E, Kalra S,et al. Current status of drug screening and disease modelling in human pluripotent stem cells[J]. Bioessays, 2013, 35(3):281-298. [11] Hoekstra M, Mummery CL, Wilde AA, et al. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias[J]. Front Physiol, 2012, 3:346. [12] Gerull B, Heuser A, Wichter T,et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy[J]. Nat Genet, 2004, 36(11):1162-1164. [13] Ma D, Wei H, Lu J, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy[J]. Eur Heart J, 2013, 34(15):1122-1133. [14] Fatima A, Dittmann S, Kaifeng S, et al. Derivation of induced pluripotent stem (iPS) cells from a patient with an arrhythmogenic right ventricular cardiomyopathy (ARVC)[J]. J Stem Cells Regen Med, 2010, 6(2):97. [15] Caspi O, Huber I, Gepstein A,et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells[J]. Circ Cardiovasc Genet, 2013, 6(6):557-568. |